Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
BioConferenceLive

New Study Using MR Technology to Revolutionize Disease Research

By BiotechDaily International staff writers
Posted on 26 Dec 2013
Image: The Siemens’ Magnetom Aera 1.5T MRI system (Photo courtesy of Siemens Healthcare).
Image: The Siemens’ Magnetom Aera 1.5T MRI system (Photo courtesy of Siemens Healthcare).
Image: The MAGNETOM Skyra 3T MRI (Photo courtesy of Siemens Healthcare).
Image: The MAGNETOM Skyra 3T MRI (Photo courtesy of Siemens Healthcare).
A world-leading health research resource based in the United Kingdom is establishing an imaging study to help scientists gain a more comprehensive determination of a wide range of diseases including cancer, dementia, and bone, heart, and brain disorders.

Utilizing the magnetic resonance imaging (MRI) capabilities of a Magnetom Aera and a Magnetom Skyra, developed by Siemens Healthcare (Erlangen, Germany), UK Biobank (Manchester, UK) expects their research project to be the most thorough study of its kind ever conducted. The MR systems will be used to obtain the vital translational research images of the study participants’ hearts and brains. Bone scans and scanning of the carotid artery (in the neck) are also planned.

In the most part funded by the UK Department of Health, Medical Research Council, and Wellcome Trust charity, UK Biobank will track the health of 500,000 British citizens over many years. The imaging part of the project, due to take place in spring 2014, will be the first time researchers have endeavored to image so many people in a single study. It is expected that the research will provide further data for scientists and clinicians trying to develop a better understanding of disorders that cause disability, pain, and premature death.

The Magnetom Aera and Skyra MR systems feature 48 radiofrequency (RF) channels as standard and lightweight coils. The systems’ open bore design with a 70-cm-wide aperture, allows a wide range of body types to be scanned either head or feet first, substantially optimizing comfort for the study participants. The systems also feature TimTM 4G (Total imaging matrix) and DotTM (Day optimizing throughput) technology integration for high-resolution imaging, improved efficiency, and enhanced productivity.

“UK Biobank is the major health research success story of recent decades. Our 500,000 participants have already provided lots of information about their health, lifestyles, and wellbeing, as well as blood, urine, and saliva samples for long-term storage and analysis, including genetic research,” noted Prof. Rory Collins, lead investigator at UK Biobank. “Adding this detailed extra information will help in many ways. For instance, it may help to identify early changes that indicate the start of disease, and it may suggest new ways to slow that process, or to prevent the disease altogether.”

“Siemens MR technology is already pivotal to many imaging research projects across the UK and we are delighted to take this one step further by taking part in one of the most detailed imaging studies of its kind,” stated Jane Kilkenny, MR business manager at Siemens Healthcare. “We look forward to supporting the project with the Magnetom Aera and Skyra’s excellent image quality and rapid acquisition times, with the end goal of producing images of a quality that can help with pioneering research into the cause and treatment of major diseases.”

UK Biobank is hosted by the University of Manchester (UK) and supported by the National Health Service (NHS). It works with researchers from a large number of British universities. The medical research project is a nonprofit charity and had initial funding of approximately GBP 62 million.

Related Links:

Siemens Healthcare
UK Biobank



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.